The switch from etanercept originator to SB4: data from a real-life experience on tolerability and persistence on treatment in joint inflammatory diseases.

Cosimo BruniStefano GentileschiGiovanni PaciniCaterina BaldiMarco CapassoniLorenzo TofaniMarco BardelliLaura CometiLuca CantariniFrancesca NacciMichele VietriFrancesca BartoliGinevra FioriBruno FredianiMarco Matucci-Cerinic

Published in: Therapeutic advances in musculoskeletal disease (2020)

Our real-life data confirm the safety profile of switching from ETN to SB4, with slightly higher treatment persistence rates compared with other real-life registries.

Keyphrases

rheumatoid arthritis
randomized controlled trial
oxidative stress
machine learning
open label
ankylosing spondylitis
systemic lupus erythematosus
double blind